

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
17 April 2025 (17.04.2025)



(10) International Publication Number
WO 2025/080726 A1

(51) International Patent Classification:

A61K 31/404 (2006.01) C12Q 1/6886 (2018.01)
A61P 35/00 (2006.01) G01N 33/574 (2006.01)
C07K 14/47 (2006.01)

(21) International Application Number:

PCT/US2024/050588

(22) International Filing Date:

09 October 2024 (09.10.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/589,229	10 October 2023 (10.10.2023)	US
63/566,417	18 March 2024 (18.03.2024)	US
63/632,458	10 April 2024 (10.04.2024)	US
63/669,209	09 July 2024 (09.07.2024)	US

(71) Applicant: **PMV PHARMACEUTICALS, INC.**

[US/US]; 400 Alexander Park Drive, 3rd Floor, Princeton,
New Jersey 08540 (US).

(72) Inventors: **ALLAND, Leila**; c/o PMV Pharmaceuticals,

Inc., 400 Alexander Park Drive, 3rd Floor, Princeton, New
Jersey 08540 (US). **FELLOUS, Marc**; c/o PMV Pharma-
ceuticals, Inc., 400 Alexander Park Drive, 3rd Floor, Prince-

ton, New Jersey 08540 (US). **JALOTA, Deepika**; c/o PMV
Pharmaceuticals, Inc., 400 Alexander Park Drive, 3rd Floor,
Princeton, New Jersey 08540 (US). **PUZIO-KUTER, An-
na**; c/o PMV Pharmaceuticals, Inc., 400 Alexander Park
Drive, 3rd Floor, Princeton, New Jersey 08540 (US). **XAN-
THOS, Zacharias**; c/o PMV Pharmaceuticals, Inc., 400
Alexander Park Drive, 3rd Floor, Princeton, New Jersey
08540 (US).

(74) Agent: **SCHWAMB, Charles B.** et al.; WILSON
SONSINI GOODRICH & ROSATI, PC, 650 Page Mill
Road, Palo Alto, California 94304 (US).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(54) Title: METHODS OF TREATING CONDITIONS WITH MUTANT P53 REACTIVATING COMPOUNDS

(57) Abstract: Mutations in oncogenes and tumor suppressors contribute to the development and progression of cancer. The present disclosure describes compounds and methods that restore DNA binding affinity of p53 mutants, and the use of diagnostic assays for guiding treatment of cancer in subjects with said compounds. The compounds of the present disclosure can bind to mutant p53 and restore the ability of the p53 mutant to bind DNA and activate downstream effectors involved in tumor suppression. The disclosed compounds can be used to reduce the progression of cancers that contain a p53 mutation.



Baseline



Post-cycle 3

FIGURE 6

WO 2025/080726 A1

[Continued on next page]

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*

— *with sequence listing part of description (Rule 5.2(a))*